$JAZZ · Jazz Pharmaceuticals plc SEC Filings
Position Tracker tracks 3 SEC EDGAR filings for Jazz Pharmaceuticals plc ($JAZZ) from October 26, 2026 through November 2, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$JAZZ 10-Q — Jazz Pharmaceuticals plc
A $754M one-time charge masks strong 10%+ revenue growth across Jazz's core franchises, but the Actio bet and mounting ANDA challenges for Epidiolex and Zepzelca create a binary…
$JAZZ 8-K — Jazz Pharmaceuticals plc
A rare combination: double-digit revenue growth and raised guidance alongside a massive GAAP loss — the $754M IPR&D charge masks underlying commercial momentum across sleep, epi…
$JAZZ 8-K — Jazz Pharmaceuticals plc
A ~$755 million one-time charge wiping ~$11.00 off EPS is a material financial event for a $13.35B biopharma — investors need to separate the acquisition noise from core operati…